A panel of experts discusses molecular testing and the use of targeted agents in lung and breast cancers, including best practices for ordering testing and how to factor results into treatment decisions.
A panel of experts in oncology review the use of antibody drug conjugates (ADCs) in breast and gastric cancers, defining optimal management of ADC-related adverse events.
Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive®
A distinguished panel of experts in hematologic malignancies builds a lively discussion on recent clinical trials and potential advancements in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.
Expert panelists elucidate the evolving field of graft versus host disease management, highlighting novel therapies and treatment approaches.
Expert panelists review new data on the management of immune thrombocytopenia and consider how these data may impact clinical practice.
A panel of experts discusses newly presented data from ASCO 2022 and how it affects potential treatment approaches for relapsed/refractory DLBCL.
Expert hematologist-oncologists Ajai Chari, MD; Krina Patel MD; Christina Gasparetto, MD; Rafael Fonseca, MD; and Omar Nadeem, MD, review data from ASCO and share updates on the management of multiple myeloma.
An expert panel discusses recent updates in the treatment of myeloproliferative neoplasms from ASCO 2022.
Expert oncologists Tanios Bekaii-Saab, MD; Anthony El-Khoueiry, MD; Pierre Gholam, MD; Arndt Vogel, MD; and Mark Yarchoan, MD, review data from ASCO 2022 and discuss updates in the management of HCC.
Expert oncologists Benjamin Levy, MD; Chaitali Nangia, MD; Jessica Donington, MD; Jonathan Wesley Riess, MD; Alexander Spira, MD; and Heather Wakelee, MD, review data from ASCO 2022 and updates in the management of NSCLC.
Expert oncologists Evan Y. Yu, MD; Andrew J. Armstrong, MD, MSc; Pedro C. Barata, MD, MSc; Tanya B. Dorff, MD; and Mary-Ellen Taplin, MD, review data from ASCO 2022 and discuss updates on the management of prostate cancer.
A panel of experts discuss how recent data from ASCO 2022 has changed the treatment landscape for small cell lung cancer.
Expert oncologists Andy Seidman, MD; Vijayakrishna Gadi, MD, PhD; Tiffany Traina, MD; William Gradishar, MD; and Stephanie Graff, MD, review data from ASCO 2022 and share updates in the management of HER2+ and HER2-low breast cancer.
Expert oncologists Hope S. Rugo, MD, FASCO; Aditya Bardia, MD, MPH; Komal Jhaveri, MD, FACP; Mark Pegram, MD; and Anne O'Dea, MD, review data from recent conferences and discuss updates in the management of HR+/HER2- breast cancer.
A panel of expert oncologists discusses updates in advanced non-small cell lung cancer and the evolving treatment landscape, and its impact on clinical practice.
Experts engage in discussion on patient profiles to review updated treatment approaches and sequencing in patients with HER2-positive metastatic breast cancer.
Expert panelists share insight on recent updates in the management of prostate cancer presented at several key conferences.
A panel of experts discuss renal cell carcinoma (RCC) using evidence-based data presented at the ASCO GU 2022 Annual Meeting this year.
Experts in gastrointestinal cancers review recent updates to the treatment landscape of advanced HCC and share insights on their impact on clinical practice.
Expert panelists reflect on the evolving landscape of HER2+ metastatic breast cancer by discussing the latest research and recent clinical trials.
Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.
Yi-Bin Chen, MD; Nelson J. Chao, MD, MBA; Hannah Choe, MD; and Sophie Paczesny, MD, PhD, review updates in the diagnosis and treatment of graft-vs-host disease.
A panel of experts discuss myeloproliferative neoplasms, focusing primarily on myelofibrosis, and share their experiences treating these diseases.
A panel discussion on changing treatment landscape of diffuse large B-cell lymphoma (DLBCL) and how new data from ASH 2021 on CAR-T therapies and antibody-drug conjugate are likely to change frontline treatment and sequencing of therapies in relapsed and refractory DLBCL going forward.
Expert panelists discuss a number of recent updates in B-cell lymphoma, particularly mantle cell lymphoma, follicular lymphoma and marginal zone lymphoma, that were presented at key conferences in 2021.
Recommendations for treating 2 clinical cases of metastatic breast cancer with antibody-drug conjugates based on supporting data and their adoption into clinical practice.
Funding from Daiichi Sanyko. Content Developed Independently by OncLive.
Expert perspectives on updates in EGFR-mutant resectable and advanced non–small cell lung cancer that were presented at key conferences in 2021 and how they have impacted the treatment landscape.
Experts in hematology/oncology review recent updates in the treatment of multiple myeloma presented at key conferences and share insight on the impact on clinical practice.
Medical oncologists and endocrinologists discuss approaches to the management of patients with differentiated thyroid cancer.
A panel of experts discuss basal cell carcinoma and cutaneous squamous cell carcinoma therapeutic agents in depth as they analyze clinical case scenarios.
